2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

target protein ligand-linker conjugate

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-132943A
    BRD4 ligand-Linker Conjugate 1 TFA

    		Target Protein Ligand-Linker Conjugates Cancer
    BRD4 ligand-Linker Conjugate 1 TFA (compound 106-1) is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs .
    BRD4 ligand-Linker Conjugate 1 TFA
  • HY-168693
    Target Protein Ligand-Linker Conjugates 2

    		Target Protein Ligand-Linker Conjugates
    Target Protein Ligand-Linker Conjugates 2 is a conjugate of the Target Protein Ligand and Linker, consisting of Desmethyl-QCA276 (HY-44103) and the corresponding Linker. Target Protein Ligand-Linker Conjugates 2 can be used to synthesize PROTAC BD-9136 (HY-149878) .
    Target Protein Ligand-Linker Conjugates 2
  • HY-169488
    SMARCA2 ligand-12-3-methylazetidine

    		Epigenetic Reader Domain Target Protein Ligand-Linker Conjugates Cancer
    SMARCA2 ligand-12-3-methylazetidin is a target protein ligand-linker conjugate that incorporates a ligand for SMARCA2 (HY-169487), and a PROTAC linker (HY-W052601), which recruit E3 ligases. SMARCA2 ligand-12-3-methylazetidin can be used to synthesize PROTAC SMARCA2 degrader-25 (HY-169276) .
    SMARCA2 ligand-12-3-methylazetidine
  • HY-153424
    PROTAC SMARCA2 degrader-1

    		Target Protein Ligand-Linker Conjugates Cancer
    PROTAC SMARCA2 degrader-1 (compound ex7) is a BRM2 (SMARCA2) degrader (DC50<0.1 μM). PROTAC SMARCA2 degrader-1 is also an E3 ubiquitin ligase binding linker useful in research of cancers. PROTAC SMARCA2 degrader-1 is a target protein ligand-linker conjugate .
    PROTAC SMARCA2 degrader-1
  • HY-132943
    BRD4 ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates Cancer
    BRD4 ligand-Linker Conjugate 1 is a target protein ligand-linker conjugate that can be used in the synthesis of PROTACs.
    BRD4 ligand-Linker Conjugate 1
  • HY-170987
    FKBP12 Ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates FKBP Cancer
    FKBP12 Ligand-Linker Conjugate 1 is the conjugate composed of a target protein ligand for FKBP12 and a linker. FKBP12 Ligand-Linker Conjugate 1 can be used for synthesis of PROTAC degrader MC-25B (HY-170983) .
    FKBP12 Ligand-Linker Conjugate 1
  • HY-169357
    Acepromazine-1-Piperazinepropanamine

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Acepromazine-1-Piperazinepropanamine (compound 10) is a synthesized E3 ligase ligand-linker conjugate (E3 Ligase Ligand-Linker Conjugate) that incorporates a cereblon ligand and a linker. Acepromazine-1-Piperazinepropanamine can be connected to the target protein ligand to form a PROTAC molecule, TrimTAC1 (HY-169355) .
    Acepromazine-1-Piperazinepropanamine
  • HY-147225
    TSPO Ligand-Linker Conjugates 1

    		AUTACs Mitophagy Neurological Disease Metabolic Disease Cancer
    TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via mitophagy, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes .
    TSPO Ligand-Linker Conjugates 1
  • HY-172266
    FKBP12 Ligand-Linker Conjugate 2

    		Target Protein Ligand-Linker Conjugates Others
    FKBP12 Ligand-Linker Conjugate 2 is a conjugate of the FKBP12 target protein ligand and a linker, and it can be used for the synthesis of FKBP12 PROTAC FM4 (HY-172265) .
    FKBP12 Ligand-Linker Conjugate 2
  • HY-173137
    KDM4 Ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates Others
    KDM4 Ligand-Linker Conjugate 1 is a conjugate of a KDM4 target protein ligand and a linker, and can be used for the synthesis of PROTAC KDM4 degrader-1 (HY-173135) .
    KDM4 Ligand-Linker Conjugate 1
  • HY-170769
    FLT3 Ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates FLT3 Cancer
    FLT3 Ligand-Linker Conjugate 1 (compound 7) contains the FLT3 ligand and a PROTAC linker, which can recruit the E3 ligase VHL. FLT3 Ligand-Linker Conjugate 1 can be used to synthesize the PROTAC RSS0680 (HY-148062). PROTAC RSS0680 is a bifunctional compound that targets protein degradation of kinases .
    FLT3 Ligand-Linker Conjugate 1
  • HY-174357
    HPK1 ligand 3-dimethylph tetrahydropyridine

    		Target Protein Ligand-Linker Conjugates Cancer
    HPK1 ligand 3-dimethylph tetrahydropyridine is a Target Protein Ligand-Linker Conjugate. HPK1 ligand 3-dimethylph tetrahydropyridine can be used to synthesize PROTAC HPK1 Degrader-4 (HY-174135) .
    HPK1 ligand 3-dimethylph tetrahydropyridine
  • HY-174409
    HDAC6 ligand-Linker Conjugate 1

    		Target Protein Ligand-Linker Conjugates HDAC Cancer
    HDAC6 ligand-linker conjugate 1 is a conjugate of HDAC6 ligand and linker, which can be used to synthesize PROTACs such as PROTAC HDAC6 degrader 5 (HY-174401) .
    HDAC6 ligand-Linker Conjugate 1
  • HY-176263
    TH10184-octanedioic acid

    		Target Protein Ligand-Linker Conjugates Cancer
    TH10184-octanedioic acid is a conjugate of the NUDT5 ligand (HY-176262) and the linker (HY-W001958). TH10184-octanedioic acid can be used for synthesizing PROTAC NUDT5 degrader DDD2 (HY-176261) .
    TH10184-octanedioic acid
  • HY-176124
    CDK2 ligand-2

    		Ligands for Target Protein for PROTAC Cancer
    CDK2 ligand-2 is a PROTAC target protein ligand (Ligands for Target Protein for PROTAC). CDK2 ligand-2 combined with E3 Ligase Ligand-linker Conjugate 184 (HY-176125) can be used to synthesize PROTAC degrader (CDK2 degrader 2 (HY-163815)) .
    CDK2 ligand-2
  • HY-131886
    Pomalidomide 4'-alkylC4-acid

    		E3 Ligase Ligand-Linker Conjugates Cancer
    Pomalidomide 4'-alkylC4-acid (linker 16) is a E3 ligase ligand-linker conjugate. Pomalidomide 4'-alkylC4-acid contains a cereblon ligand, an alkylC4 chain, and a terminal acid. Pomalidomide 4'-alkylC4-acid can be used to couple with target protein ligands to synthesize PROTAC .
    Pomalidomide 4'-alkylC4-acid
  • HY-170332
    PROTAC ER Degrader-15

    		PROTACs Estrogen Receptor/ERR Cancer
    PROTAC ER Degrader-15 (Compound 40) is an orally active degrader of the estrogen receptor (ER) with anticancer activity，which can be used in breast cancer research (Pink: Target Protein Ligand (HY-170334); Black: Linker (HY-30756); Blue: E3 Ligase Ligand (HY-138793); E3 Ligase Ligand-Linker Conjugate (HY-169979)) .
    PROTAC ER Degrader-15
  • HY-170808
    PROTAC BRD4 Degrader-28

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-28 (Compound 4) is a PROTAC degrader targeting BRD4. PROTAC BRD4 Degrader-28 is promising for research of cancers (Pink: target protein ligand JQ-1 (carboxylic acid) (HY-78695); Black+ Blue: E3 ubiquitin ligase ligand-Linker conjugate Thalidomide-O-amido-C3-NH2 (HY-115560)) .
    PROTAC BRD4 Degrader-28
  • HY-170828
    SMD-1087

    		PROTACs SWI/SNF Complex Others
    SMD-1087 is a PROTAC that selectively targets SMARCA2 (DC50=8 nM, Dmax=89%) and SMARCA4 with a DC50 of 1 μM. SMD-1087 consists of the E3 ligase ligand (S,R,S)-AHPC-Me (blue part) (HY-112078), the target protein ligand SMI-1074 (red part) (HY-170817), and the PROTAC linker (1r,4r)-tert-Butyl 4-(bromomethyl)cyclohexanecarboxylate (black part) (HY-W890392). Among them, its target protein ligand + Linker part corresponds to SMARCA2 Ligand-Linker Conjugate-1 (HY-170829) .
    SMD-1087
  • HY-172265
    FKBP12 PROTAC FM4

    		PROTACs Cancer
    FKBP12 PROTAC FM4 is a PROTAC degrader of MTH1, with a DC50 values of 0.09–0.22 nM. FKBP12 PROTAC FM4 is composed of PROTAC target protein ligand AP1867-3-(aminoethoxy) (HY-129363) (red part), E3 ligase ligand MTH1 ligand 1 (HY-134724) (blue part) and PROTAC Linker t-Boc-N-amido-PEG5-acetic acid (HY-W190962) (black part), among which the conjugate of PROTAC target protein ligand + Linker is FKBP12 Ligand-Linker Conjugate 2 (HY-172266) .
    FKBP12 PROTAC FM4
  • HY-170852
    QZ2135

    		PROTACs RET Cancer
    QZ2135 (compound 20) is a RET-targeted PROTAC degrader with in vivo antitumor properties in a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The degradation activities of QZ2135 targeting KIF5B-RET have DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C), respectively. QZ2135 is composed of a target protein ligand (red part) RET ligand-3 (HY-170853), an E3 ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC Linker (black part) 7-Iodohept-1-yne (HY-W587352), in which the target protein ligand + linker form a conjugate RET Ligand-Linker Conjugate-1 (HY-170854) .
    QZ2135
  • HY-170859
    AH078

    		Casein Kinase Others
    AH078 (compound 37) is a PROTAC degrader that selectively targets CK1δ and CK1ε, and has low targeting for CK1α. AH078 consists of PROTAC linker (black part) Monomethyl octanoate (HY-W001958), target protein ligand (red part) (HY-170860) CK1δ/CK1ε liagnd-1 and E3 ligase ligand (blue part) E3 ligase Ligand 58 (HY-170861). Among them, E3 ligase ligand + linker can form a conjugate E3 Ligase Ligand-linker Conjugate 163 (HY-170862) .
    AH078
  • HY-160221
    PROTAC AR Degrader-7

    		PROTACs Androgen Receptor Cancer
    PROTAC AR Degrader-7 (compound 99) is a PROTAC targeting androgen receptor with an IC50 value of 3 nM. PROTAC AR Degrader-7 is composed of PROTAC target protein ligand AR ligand-32 (HY-170303) (red part), E3 ligase ligand E3 ligase Ligand 44 (HY-170304) (blue part) and PROTAC Linker N-Boc-piperazine (HY-30105) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 145 (HY-170305) .
    PROTAC AR Degrader-7
  • HY-176167
    mTOR ligand 1-C6-amino

    		Ligands for Target Protein for PROTAC Cancer
    mTOR ligand 1-C6-amino is a conjugate of a target protein ligand (HY-B0795) and a linker (HY-W008296). mTOR ligand 1-C6-amino can be used to synthesize PROTAC PD-M6 (HY-176166) .
    mTOR ligand 1-C6-amino
  • HY-142621
    BCPyr

    		PROTACs Btk Cancer
    BCPyr is a PROTAC-class BTK degrader (DC50 = 800 nM) . BCPyr consists of a PROTAC target protein ligand (red part) BTK ligand 11 (HY-168314), an E3 ubiquitin ligase ligand (blue part) E3 ligase Ligand 20 (HY-135997), and a PROTAC linker (black part) (5-(Bromomethyl)pyrazin-2-yl)methanol (HY-168315). E3 ubiquitin ligase+linker can form E3 Ligase Ligand-linker Conjugate 146 (HY-168316).
    BCPyr
  • HY-168274
    PROTAC TRIB2 degrader-1

    		PROTACs Apoptosis Cancer
    PROTAC TRIB2 degrader-1 (Compound 5k) is an effective TRIB2 degrader that selectively induces TRIB2 degradation through the CRBN-dependent ubiquitin-proteasome pathway. PROTAC TRIB2 degrader-1 can inhibit cell proliferation and induce cell apoptosis, and can be used in cancer research. (Target protein ligand (Pink): HY-168275; linker (black): HY-168276; E3 Ligase Ligand-Linker Conjugates: HY-168277; E3 ligase (Blue): HY-W023573) .
    PROTAC TRIB2 degrader-1
  • HY-174135
    PROTAC HPK1 Degrader-4

    		PROTACs MAP4K Cancer
    PROTAC HPK1 Degrader-4 (compound E3) is a selective and orally active PROTAC HPK1 degrader with a DC50 of 3.16 nM. PROTAC HPK1 Degrader-4 demonstrates >1000-fold selectivity over GLK. PROTAC HPK1 Degrader-4 promotes immune activation. PROTAC HPK1 Degrader-4 can be used for the study of colon cancer and lymphoma (Pink: ligand for target protein (HY-174355); Blue: ligand for E3 ligase CRBN (HY-45808); Black: Linker (HY-174356); Target protein ligand-linker Conjugate (HY-174357)) .
    PROTAC HPK1 Degrader-4
  • HY-170869
    PROTAC FGFR1 degrader-1

    		PROTACs FGFR Cancer
    PROTAC FGFR1 degrader-1 (compound S2H) is a PROTAC degrader targeting FGFR1, with IC50=26.81 nM and DC50=39.78 nM in KG1a cells. PROTAC FGFR1 degrader-1 is composed of CRBN-type E3 ligase ligand (blue part) Pomalidomide (HY-10984), target protein ligand (red part) FGFR1 ligand-1 (HY-170871), and PROTAC linker (black part) 9-Bromononanoic acid (HY-W007587), in which the E3 ligase ligand and linker form a conjugate E3 Ligase Ligand-linker Conjugate 164 (HY-170870) .
    PROTAC FGFR1 degrader-1
  • HY-157228
    ACBI3

    		PROTACs Ras Cancer
    ACBI3 (compound 7) is a PROTAC targeting KRAS. ACBI3 is composed of PROTAC target protein ligand pan-KRAS degrader 1 (HY-162960) (red part), E3 ligase ligand E3 ligase Ligand 43 (HY-401613) (blue part) and PROTAC Linker 1-Bromo-4-(ethynyloxy)butane (HY-169992) (black part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 143 (HY-169995). ACBI3 achieves in vivo degradation of oncogenic KRAS, resulting in durable pathway modulation and tumor regressions in KRAS mutant xenograft mouse models .
    ACBI3
  • HY-159651
    PTOTAC HSD17B13 degrader 1

    		PROTACs 17β-HSD Cancer
    PTOTAC HSD17B13 degrader 1 (compound 1) is a PROTAC targeting 17β-HSD 13 (HSD17B13). PTOTAC HSD17B13 degrader 1 is composed of PROTAC target protein ligand HSD17B13 degrader 2 (HY-159662) (red part), PROTAC Linker tert-Butyl 5-bromoisoindoline-2-carboxylate (HY-W003696) (black part) and E3 ubiquitin ligase ligand E3 ligase Ligand 31 (HY-159660) (blue part), among which the conjugate of E3 ubiquitin ligase ligand + Linker is E3 Ligase Ligand-linker Conjugate 114 (HY-159661) [1] .
    PTOTAC HSD17B13 degrader 1
  • HY-170347
    PROTAC SMARCA2/4 degrader-36

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC SMARCA2/4 degrader-36 (Compound 29) is an effective dual degrader of SMARCA2/4,with DC50 values of 0.22 nM and 0.85 nM for SMARCA2 and SMARCA4, respectively. PROTAC SMARCA2/4 degrader-36 has anti-cell proliferation activity (Pink: Target Protein Ligand (HY-170354); Black: Linker (HY-W895794); Blue: E3 Ligase Ligand (HY-170353); E3 Ligase Ligand-Linker Conjugate (HY-170356)) .
    PROTAC SMARCA2/4 degrader-36
  • HY-170669
    PROTAC XPO1 degrader-1

    		PROTACs CRM1 Apoptosis NF-κB Cancer
    PROTAC XPO1 degrader-1 (Compound 2c) is an XPO1 degrader. PROTAC XPO1 degrader-1 exhibits anti-proliferative effects, can induce cell apoptosis, inhibit NF-κB activity, and cause cell cycle arrest in the G1 phase. PROTAC XPO1 degrader-1 can be used in research on hematological malignancies (Pink: Target Protein Ligand (HY-170672); Black: Linker (HY-W010525); Blue: E3 Ligase Ligand (HY-170671); E3 Ligase Ligand-Linker Conjugate (HY-170673)) .
    PROTAC XPO1 degrader-1
  • HY-145925C
    (S,R)-CFT8634

    		PROTACs Epigenetic Reader Domain Cancer
    (S,R)-CFT8634 (compound 176) is a selective and orally active PROTAC-class BRD9 protein degrader. (S,R)-CFT8634 has the potential to study BRD9-mediated diseases, including but not limited to abnormal cell proliferation. (S,R)-CFT8634 consists of a target protein ligand (red part) BRD9 ligand-5 (HY-169988), an E3 ligase ligand (blue part) CRBN ligand-11 (HY-169989), and a PROTAC linker (black part) 1-(3,3-Difluoro-4-piperidinyl)piperazine (HY-169991). E3 ligase ligand and linker can form E3 Ligase Ligand-linker Conjugate 142 (HY-169990) .
    (S,R)-CFT8634
  • HY-173333
    PROTAC SMARCA2/4 degrader-38

    		PROTACs Epigenetic Reader Domain Apoptosis Cancer
    PROTAC SMARCA2/4 degrader-38 is a degrader SMARCA2/4 PROTAC (DC50: 3.0 nM and 4.0 nM respectively). PROTAC SMARCA2/4 degrader-38 promotes the ubiquitination and degradation of SMARCA2/4. PROTAC SMARCA2/4 degrader-38 blocks the G0/G1 cell cycle and induces apoptosis. PROTAC SMARCA2/4 degrader-38 can be used in acute myeloid leukemia (AML) research. (Pink: SMARCA2/4 ligand; Blue: VHL ligand (HY-112078); Black: linker; Target Protein Ligand-Linker Conjugates (HY-173343)) .
    PROTAC SMARCA2/4 degrader-38
  • HY-170824
    SMD-3236

    		PROTACs Epigenetic Reader Domain Cancer
    SMD-3236 is a SMARCA2-targeted PRAOTAC degrader designed based on SMARCA ligands and VHL-1 ligands, with long-lasting antitumor activity in vivo. SMARCA2 is a synthetic lethal target in SMARCA4-deficient cancer cells, and SMD-3236 has a 2000-fold selectivity for degradation of SMARCA2 over SMARCA4, with a DC50< 1 nM and a Dmax>95%. SMD-3236 can induce SMARCA2 loss in tumor tissues while retaining SMARCA4 protein, and inhibit tumor growth in the H838 smarca4-deficient human cancer xenograft model. SMD-3236 is composed of target protein ligand (red part) SMI-1074 (HY-170817), PROTAC linker (black part) (trans-4-Ethynylcyclohexyl)methyl methanesulfonate (HY-170825), and E3 ligase ligand (blue part) SMARCA2 ligand-14 (HY-170826), of which the E3 ligase ligand and linker form a conjugate E3 Ligase Ligand-linker Conjugate 159 (HY-170827) .
    SMD-3236
  • HY-170820
    XYD049

    		Molecular Glues Cancer
    XYD049 (compound 7d) is a CRBN-type molecular glue targeting GSPT1 (DC50=19 nM), which can be used for the research of MYC-driven castration-resistant prostate cancer (CRPC). XYD049 can effectively inhibit the growth of 22Rv1 cells (IC50=7 nM) and has in vivo antitumor efficacy. XYD049 downregulates the CRPC-related oncogenes in 22Rv1 cells, including AR, AR-v7, PSA, and c-Myc. XYD049 is composed of a molecular glue linker (black part) NH2-C5-NH-Boc (HY-W004710), a CRBN-type E3 ligase ligand (blue part) Thalidomide 4-fluoride (HY-41547), and a target protein ligand (red part) GSPT1 ligand-1 (HY-170821), in which the E3 ligase ligand + liner form a conjugate E3 Ligase Ligand-linker Conjugate 158 (HY-170822) .
    XYD049

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: